Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. (Beta Bionics) due to significant stock losses and possible misleading statements made by the company [2][5]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is also referred to as Beta Bionics and is listed on NASDAQ under the ticker BBNX [2]. - The company has experienced a significant decline in its stock price, with shares plunging approximately 37% on January 9, 2026, following an announcement regarding fewer patient starts than analysts had estimated for the fourth quarter [5]. Group 2: Legal Investigation - The investigation by Faruqi & Faruqi focuses on whether Beta Bionics issued misleading statements or failed to disclose important information that could affect investors [5]. - Investors who have suffered significant losses in Beta Bionics stock or options are encouraged to contact the law firm to discuss their legal rights [1].

Group 1 - Holzer & Holzer, LLC is investigating Mereo BioPharma Group plc for potential compliance issues with federal securities laws following the announcement of Phase 3 study results for setrusumab, which did not achieve statistical significance against primary endpoints [1] - The Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta revealed that neither study met the primary endpoints of reducing annualized clinical fracture rates compared to placebo or bisphosphonates [1] - Following the announcement of the study results, Mereo's stock price experienced a decline [1]

Core Viewpoint - Mereo BioPharma Group plc is under investigation for potential violations of federal securities laws following disappointing clinical trial results that led to a significant drop in stock price [1][2]. Group 1: Company Performance - On December 29, 2025, Mereo BioPharma announced results from its Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI), reporting that neither study achieved its primary efficacy endpoint of reducing the annualized clinical fracture rate compared to placebo [2]. - Following the announcement, Mereo's stock price plummeted over 89%, opening at $0.25 per share [2]. Group 2: Legal Investigation - Levi & Korsinsky has commenced an investigation into Mereo BioPharma Group plc regarding potential violations of federal securities laws, inviting investors who suffered losses to explore recovery options [1][3].

Core Insights - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following a Complete Response Letter (CRL) from the FDA regarding its new drug application for relacorilant [1][2] - The FDA's decision was based on the need for additional evidence of effectiveness despite acknowledging previous trial results [2] - Following the announcement, Corcept's stock price experienced a significant drop of $31.42, equating to a 44.76% decrease, marking a new 52-week low [2][3] Company Overview - Corcept Therapeutics focuses on developing treatments for patients with conditions related to hypercortisolism, specifically hypertension [1] - The company has faced challenges in gaining FDA approval for its drug relacorilant, which has implications for its market position and investor confidence [2] Market Reaction - The stock price decline to $38.78 per share reflects investor concerns over the FDA's decision and the potential impact on the company's future [2][3] - The drop in stock price indicates a significant loss of value for shareholders, prompting investigations into the company's compliance with securities laws [1][3]

Core Viewpoint - Fermi Inc. is facing potential legal claims due to allegations of misleading statements regarding its Project Matador campus and tenant commitments, which have led to significant stock price declines following the termination of a key funding agreement [5][8]. Group 1: Company Overview - Fermi Inc. (NASDAQ: FRMI) completed its initial public offering on October 1, 2025, offering approximately 32.5 million shares at $21.00 per share [6]. - The company aimed to develop a large electric generation campus for AI data centers and had identified a significant tenant for its Project Matador site [6]. Group 2: Legal Issues - The complaint against Fermi alleges violations of federal securities laws, including overstating tenant demand and failing to disclose risks related to funding commitments for Project Matador [5]. - The First Tenant had initially agreed to advance up to $150 million for construction costs but terminated this agreement on December 11, 2025, leading to a market reaction that saw Fermi's stock price drop over 33% to $10.09 per share [7][8]. Group 3: Investor Actions - Faruqi & Faruqi, LLP is encouraging investors who suffered losses to contact them to discuss their legal options, with a deadline of March 6, 2026, to seek the role of lead plaintiff in a federal securities class action [2][10].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for allegedly making materially false and misleading statements regarding the company's Long Island City property and its leasing value as a life-science destination during the specified Class Period from January 27, 2025, to October 27, 2025 [3][7]. Allegation Details - The lawsuit claims that the defendants provided overwhelmingly positive statements while concealing adverse facts about the true state of the Long Island City property [3]. - It is alleged that the company's claims regarding the leasing value of the LIC property were misleading and lacked a reasonable basis, particularly concerning the Megacampus™ strategy [3]. - As a result, the statements made by the defendants about the company's business, operations, and prospects were materially false and misleading throughout the Class Period [3]. Next Steps - Investors who purchased or acquired Alexandria shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][7]. - There is no cost or obligation for investors to inquire about their legal options [4]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation, including securities and commercial litigation [5]. - The firm operates nationwide and handles cases in both federal and state courts [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ardent To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ardent between July 18, 2024 and November 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Jan. 24, 2026 (GLOBE NEWSWIRE) -- Faruqi & ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about its Phase 3 PALISADE-3 trial of fasedienol for social anxiety disorder [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Trial Results and Stock Impact - On December 17, 2025, Vistagen announced that its PALISADE-3 study did not meet its primary efficacy endpoint, resulting in a significant stock decline of $3.50 or 80.27%, closing at $0.86 [6]. - The study failed to show statistically significant improvement in anxiety reduction compared to placebo, raising concerns about the company's disclosures [5][6]. Group 3: Call for Information - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Vistagen's conduct [8].

Core Insights - Holzer & Holzer, LLC is investigating Newegg Commerce, Inc. for potential compliance issues with federal securities laws following the announcement of an investigation into the company's chairman, He Zhitao, who has been detained [1] Company Summary - Newegg disclosed on January 20, 2026, that it received a notice regarding the investigation and detention of its chairman and largest stockholder, He Zhitao [1] - The announcement led to a decline in Newegg's stock price [1] Legal Context - Shareholders who purchased Newegg stock and experienced losses are encouraged to contact Holzer & Holzer for legal assistance regarding their rights [2] - Holzer & Holzer, LLC is recognized for its representation of shareholders and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Bath & Body Works, Inc. due to allegations of misleading statements and failure to disclose critical information regarding the company's financial performance and business strategy [4][6]. Financial Performance - Bath & Body Works reported a 1% year-over-year decline in revenue for Q3 2025, missing prior guidance of 1-3% growth [7]. - The company's net income dropped by 26% to $77 million [7]. - The full-year earnings per diluted share outlook was sharply reduced from a range of $3.28 to $3.53 to "at least $2.83" [7]. Business Strategy - The company's strategy of pursuing "adjacencies, collaborations and promotions" was found to be ineffective in growing the customer base and delivering expected net sales growth [6]. - Bath & Body Works admitted that this strategy led to reduced investment in core categories and an overreliance on brand collaborations to mask weak financial results [7]. Stock Market Reaction - Following the disappointing financial disclosures, Bath & Body Works' stock price fell by $5.22, or 24.8%, closing at $15.82 per share on November 20, 2025 [8]. Legal Proceedings - Investors who suffered losses between June 4, 2024, and November 19, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][4]. - There is a deadline of March 16, 2026, for investors to seek the role of lead plaintiff in the federal securities class action against the company [4].